Peritumoral eosinophils predict recurrence in colorectal cancer

Modern Pathology

Volumn 28, Issue 3, 2015, Pages 403-413

  Harbaum, Lars ^a   Pollheimer, Marion J ^b   Kornprat, Peter ^b   Lindtner, Richard A ^c   Bokemeyer, Carsten ^a   Langner, Cord ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; EOSINOPHIL COUNT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; INTRATUMORAL EOSINOPHIL COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERITUMORAL EOSINOPHIL COUNT; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR DIFFERENTIATION; TUMOR INVASION; COLORECTAL TUMOR; EOSINOPHIL; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TUMOR RECURRENCE;

COLORECTAL NEOPLASMS; EOSINOPHILS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84938418635     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.104     Document Type: Article

References (35)

1. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2013;383:1490-1502
2. Compton CC. Optimal pathologic staging: defining stage II disease. Clin Cancer Res 2007;13:6862s-6870ss
3. Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014;232:199-209
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674
5. Roxburgh CS, McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev 2012;38: 451-466
6. Klintrup K, Makinen JM, Kauppila S, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005;41:2645-2654
7. Nielsen HJ, Hansen U, Christensen IJ, et al. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999;189:487-495
8. Fernandez-Acenero MJ, Galindo-Gallego M, Sanz J, et al. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 2000;88:1544-1548
9. Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-A histopathological and immunohistochemical study. BMC Cancer 2001;1:7
10. Fisher ER, Paik SM, Rockette H, et al. Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01). Hum Pathol 1989;20:159-163
11. Richards CH, Flegg KM, Roxburgh CS, et al. The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. Br J Cancer 2012;106:2010-2015
12. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-358
13. Sobin L, Gospodarowicz MK, Wittekind C (eds) TNM Classification of Malignant Tumors, 7th edn. Wiley-Blackwell: West Sussex, UK, 2010
14. Hamilton SR, Bosman FT, Boffetta P. Carcinoma of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, et al. (eds) World Health Organization Classification of Tumours of the Digestive System. IARC: Lyon, France; 2010, pp 131-181
15. Ueno H, Murphy J, Jass JR, et al. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002;40:127-132
16. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21:309-322
17. McGinnis MC, Bradley EL Jr, Pretlow TP, et al. Correlation of stromal cells by morphometric analysis with metastatic behavior of human colonic carcinoma. Cancer Res 1989;49:5989-5993
18. Pretlow TP, Boohaker EA, Pitts AM, et al. Heterogeneity and subcompartmentalization in the distribution of eosinophils in human colonic carcinomas. Am J Pathol 1984;116:207-213
19. Pretlow TP, Keith EF, Cryar AK, et al. Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res 1983;43:2997-3000
20. Luebbers EL, Pretlow TP, Emancipator SN, et al. Heterogeneity and prognostic significance of macrophages in human colonic carcinomas. Cancer Res 1985;45: 5196-5200
21. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 1986;39:585-589
22. Roxburgh CS, Salmond JM, Horgan PG, et al. Tumour inflammatory infiltrate predicts survival following curative resection for node-negative colorectal cancer. Eur J Cancer 2009;45:2138-2145
23. Roxburgh CS, Salmond JM, Horgan PG, et al. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 2009;249:788-793
24. Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3 T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186-192
25. Jacobsen EA, Taranova AG, Lee NA, et al. Eosinophils: singularly destructive effector cells or purveyors of immunoregulation? J Allergy Clin Immunol 2007;119:1313-1320
26. Cormier SA, Taranova AG, Bedient C, et al. Pivotal Advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol 2006;79:1131-1139
27. Mattes J, Hulett M, Xie W, et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 2003;197:387-393
28. Simson L, Ellyard JI, Dent LA, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 2007;178:4222-4229
29. Legrand F, Driss V, Delbeke M, et al. Human eosinophils exert TNF-alpha and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J Immunol 2010;185:7443-7451
30. Arinaga S, Karimine N, Takamuku K, et al. Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C. Cancer Immunol Immunother 1992;35:246-250
31. Sosman JA, Bartemes K, Offord KP, et al. Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin Cancer Res 1995;1:805-812
32. Sosman JA, Fisher SG, Kefer C, et al. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. Ann Oncol 1994;5:447-452
33. Tepper RI, Coffman RL, Leder P. An eosinophildependent mechanism for the antitumor effect of interleukin-4. Science 1992;257:548-551
34. Benatar T, Cao MY, Lee Y, et al. IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol Immunother 2010;59:805-817
35. Furuta S, Jeng YM, Zhou L, et al. IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells. Sci Transl Med 2011;3:78ra31.